| 2025 Guidance | |
| Revenue | $460 to $480 million |
| Gross Profit | $73 to $82 million |
| Adjusted EBITDA | $(8) to $(17) million |
| Free Cash Flow | $(12) to $(21) million |
The Company expects Adjusted EBITDA of approximately $(5) to $(6) million in the first quarter of 2025 primarily due to seasonal factors such as new year drug price increases and lower encounter volumes.